Related Experiment Videos
Metabotropic glutamate antagonist, MCPG, treatment of traumatic brain injury in rats
Q Z Gong1, T M Delahunty, R J Hamm
1Department of Psychology, Medical College of Virginia/Virginia Commonwealth University, Richmond 23298-0683, USA.
Abstract:
The metabotropic glutamate receptor (mGluR) antagonist, alpha-methyl-4-carboxyphenylglycine (MCPG) was administered into the left lateral ventricle 5 min prior to fluid percussion traumatic brain injury (TBI) in the rat. A single 5.0 microliters ventricular infusion of the active isomer. (+)-MCPG (0.2 mumol), significantly reduced beam walking motor deficits on days 1-5 after injury and learning/memory deficits measured on days 11-15 after injury. Neither a lower dose of (+)-MCPG (0.2 mumol) affected behavioral outcome. (+)-MCPG (0.2 mumol) did not affect systemic hemodynamic responses to injury. These results suggest that TBI induced activation of mGluRs contributes to behavioral morbidity and that blockade of certain mGluR subtypes (mGluR1, mGluR5 and/or mGluR2) may reduce these pathophysiological responses.
Insights
Administering alpha-methyl-4-carboxyphenylglycine (MCPG), a metabotropic glutamate receptor antagonist, reduced motor and memory deficits following traumatic brain injury (TBI) in rats. This suggests mGluR blockade may mitigate TBI-induced behavioral impairments.
Area of Science:
- Neuroscience
- Pharmacology
- Traumatology
Background:
- Traumatic brain injury (TBI) can lead to significant motor and cognitive impairments.
- Metabotropic glutamate receptors (mGluRs) are implicated in various neurological processes and may play a role in TBI pathophysiology.
Purpose of the Study:
- To investigate the neuroprotective potential of the mGluR antagonist alpha-methyl-4-carboxyphenylglycine (MCPG) in a rat model of TBI.
- To determine if blocking mGluRs can ameliorate behavioral deficits induced by TBI.
Main Methods:
- Rats underwent fluid percussion TBI.
- The mGluR antagonist (+)-MCPG was administered intracerebroventricularly 5 minutes before TBI.
- Behavioral assessments included motor function (beam walking) and learning/memory tests at different time points post-injury.
Main Results:
- A single dose of (+)-MCPG (0.2 mumol) significantly reduced motor deficits from days 1-5 post-TBI.
- (+)-MCPG administration also significantly improved learning and memory deficits assessed on days 11-15 post-TBI.
- The effective dose of (+)-MCPG did not alter systemic hemodynamic responses to TBI.
Conclusions:
- TBI-induced activation of mGluRs contributes to behavioral dysfunction.
- Blockade of specific mGluR subtypes (mGluR1, mGluR5, and/or mGluR2) by (+)-MCPG shows potential for reducing TBI-related behavioral morbidity.
- mGluR antagonists represent a potential therapeutic strategy for mitigating the consequences of TBI.